Clinics in Dermatology
Volume 28, Issue 1 , Pages 24-30 , January 2010

The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies

References 

  1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1:1109–1110
  2. Dreno B, Poli F. Epidemiology of acne. Dermatology. 2003;206:7–103
  3. Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol. 1997;38:115–234
  4. Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85:119–126
  5. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39:S34–S37
  6. Thomas DR. Psychosocial effects of acne. J Cutan Med Surg. 2004;8(suppl 4):3–5
  7. Koo J. The psychosocial impact of acne: patients’ perceptions. J Am Acad Dermatol. 1995;32:S26–S30
  8. Fried RG, Wechsler A. Psychological problems in the acne patient. Dermatol Ther. 2006;19:237–240
  9. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998 20;351:1871–1876
  10. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726–735
  11. Webster GF. Acne vulgaris. BMJ. 2002;325:475–479
  12. Gollnick H, Cunliffe W, Berson D, et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 suppl):S1–S37
  13. Zouboulis CC, Schagen S, Alestas T. The sebocyte culture: a model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhoea and acne. Arch Dermatol Res. 2008;300:397–413
  14. Böhm M, Luger TA. The pilosebaceous unit is part of the skin immune system. Dermatology. 1998;196:75–79
  15. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):43–49
  16. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22:360–366
  17. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne?. Exp Dermatol. 2005;14:143–152
  18. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20–27
  19. Usatine RP, Quan MA. Pearls in the management of acne: an advanced approach. Prim Care. 2000;27:289–308
  20. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs. 2003;5:301–313
  21. Burkhart CN, Gottwald L. Assessment of etiologic agents in acne pathogenesis. Skinmed. 2003;2:222–228
  22. Karvonen SL, Räsänen L, Cunliffe WJ, Holland KT, Karvonen J, Reunala T. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. Dermatology. 1994;189:344–349
  23. Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol. 2005;153:1105–1113
  24. Katsambas AD, Stefanaki C, Cunliffe WJ. Guidelines for treating acne. Clin Dermatol. 2004;22:439–444
  25. Hayashi N, Suh DH, Akamatsu H, Kawashima M Acne Study Group. Evaluation of the newly established acne severity classification among Japanese and Korean dermatologists. J Dermatol. 2008;35:261–263
  26. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol. 1979;115:571–575
  27. Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and treatment of acne. Am Fam Physician. 2004;69:2123–2130
  28. Pochi PE, Shalita AR, Strauss JS, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol. 1991;24:495–500
  29. Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol. 1993;28:572–579
  30. Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–309
  31. Jansen T, Grabbe S, Plewig G. [Clinical variants of acne]. Hautarzt. 2005;56:1018–1026
  32. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003;19:1–10
  33. Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21:86–95
  34. Geiger JM, Hommel L, Harms M, Saurat JH. Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J Am Acad Dermatol. 1996;34:513–515
  35. Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol. 2006;126:2154–2156
  36. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006;126:2178–2189
  37. Cooper AJ, Australian Roaccutane Advisory Board . Treatment of acne with isotretinoin: recommendations based on Australian experience. Australas J Dermatol. 2003;44:97–105
  38. Coates P, Adams CA, Cunliffe WJ, et al. Does oral isotretinoin prevent Propionibacterium acnes resistance?. Dermatology. 1997;195(suppl 1):4–9[discussion 38-40]
  39. Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol. 2005;153:1126–1136Erratum inBr J Dermatol 2006 154807
  40. Wozel G, Chang A, Zultak M, et al. The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res. 1991;28:158–161
  41. Papakonstantinou E, Aletras AJ, Glass E, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005;125:673–684
  42. Accutane (isotretinoin) capsules: complete product information [package insert]. Nutley (NJ): Roche Laboratories; 2007;
  43. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol. 2006;20:773–776
  44. Dréno B, Bettoli V, Ochsendorf F, et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol. 2006;16:565–571
  45. Böni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol. 2003;4:273–276
  46. Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res. 1986;278:307–313
  47. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983;23:534–539
  48. Ghaffarpour G, Mazloomi S, Soltani-Arabshahi R, Seyed KS. Oral isotretinoin for acne, adjusting treatment according to patient's response. J Drugs Dermatol. 2006;5:878–882
  49. Thielitz A, Krautheim A, Gollnick H. Update in retinoid therapy of acne. Dermatol Ther. 2006;19:272–279
  50. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol. 1992;27:S2–S7
  51. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology. 1998;196:140–147
  52. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment. Br J Dermatol. 1993;129:292–296
  53. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol. 2004;22:412–418
  54. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194:351–357
  55. Harms M. Isotretinoin: 10 years on. Dermatology. 1993;186:81–82
  56. Hermes B, Praetel C, Henz BM. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol. 1998;11:117–121
  57. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology. 1993;186:123–128
  58. Goulden V, Clark SM, McGeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997;137:106–108
  59. Kaymak Y, Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol. 2006;20:1256–1260
  60. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:644–646
  61. Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res. 2003;23:41–46
  62. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003;1:952–958
  63. Kuenzli S, Saurat JH. Retinoids. In:  Bolognia JL,  Jorizzo JL,  Rapini RP editor. Dermatology e-dition. 2nd ed.. London (UK): Mosby Elsevier; 2008;
  64. Ortonne JP. Oral isotretinoin treatment policy. Do we all agree?. Dermatology. 1997;195(suppl 1):34–37[discussion 38-40]
  65. Harms M, Masouyé I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica. 1986;172:148–153
  66. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?. Br J Dermatol. 1993;129:297–301
  67. Leyden JJ. Oral isotretinoin. How can we treat difficult acne patients?. Dermatology. 1997;195(suppl 1):29–33discussion 38-40
  68. [No authors listed] . Safe use of acne drug.. FDA Consum. 2005;39:4
  69. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45:S150–S157
  70. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp. 1988;3:273–288
  71. Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol. 1984;10:851–854
  72. Centers for Disease Control and Prevention (CDC) . Accutane-exposed pregnancies–California, 1999. MMWR Morb Mortal Wkly Rep. 2000;49:28–31
  73. Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf. 2004;3:119–129
  74. Landau M, Mesterman R, Ophir J, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol. 2001;81:350–352
  75. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45:S188–S194
  76. Goldsmith LA, Bolognia JL, Callen JP, et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004;50:900–906
  77. DiGiovanna JJ, Langman CB, Tschen EH, et al. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol. 2004;51:709–717
  78. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link?. J Am Acad Dermatol. 2001;45:S168–S175
  79. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231–1236
  80. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26:210–220
  81. Feldman SR. The moral of the isotretinoin depression story. J Dermatolog Treat. 2004;15:199
  82. Friedman T, Wohl Y, Knobler HY, et al. Increased use of mental health services related to isotretinoin treatment: a 5-year analysis. Eur Neuropsychopharmacol. 2006;16:413–416
  83. Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin. 2005;23:665–674
  84. Hull PR, D'Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol. 2003;4:493–505
  85. Enders SJ, Enders JM. Isotretinoin and psychiatric illness in adolescents and young adults. Ann Pharmacother. 2003;37:1124–1127
  86. Hendrix CW, Jackson KA, Whitmore E, et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004;75:464–475
  87. Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005;6:29–37
  88. Verros CD, Rallis E. Is oral isotretinoin the treatment of choice in moderate and severe inflammatory acne vulgaris?. J Eur Acad Dermatol Venereol. 2007;21:1270–1271

PII: S0738-081X(09)00051-0

doi: 10.1016/j.clindermatol.2009.03.005

Clinics in Dermatology
Volume 28, Issue 1 , Pages 24-30 , January 2010

Article Tools